**Author details**

Manish Dwivedi\* and Priya Giri Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, India

\*Address all correspondence to: mdwivedi@lko.amity.edu

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**25**

*Challenges in Drug Discovery against Tuberculosis DOI: http://dx.doi.org/10.5772/intechopen.97857*

[1] Koul A, Arnoult E, Lounis N, et al. The challenge of new drug discovery for [9] Early JV, Casey A,

Martinez-Grau MA, et al. Oxadiazoles have butyrate-specific conditional activity against *Mycobacterium tuberculosis*. Antimicrob Agents Chemother. 2016Jun;60(6):3608-3616.

[10] Yuan, T., & Sampson, N. S. (2018). Hit generation in TB drug discovery: From genome to granuloma. Chemical

[11] Rybniker, J.; Chen, J. M.; Sala, C.; Hartkoorn, R. C.; Vocat, A.; Benjak, A.; Boy-Rottger, S.; Zhang, M.; Szekely, R.; Greff, Z.; et al. Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion. Cell Host

[12] Abrahams GL, Kumar A, Savvi S, et al. Pathway-selective sensitization of *Mycobacterium tuberculosis* for targetbased whole-cell screening. Chem Biol.

Reviews, *118*(4), 1887-1916.

Microbe 2014, 16, 538−548.

2012 Jul 27;19(7):844-854.

2014 Sep;1323:56-75.

Neurosci. 2018

0031−2016.

drug discovery. ACS Chem.

nonreplicating *Mycobacterium tuberculosis*. Antimicrob Agents

[13] Mdluli K, Kaneko T, Upton A. Tuberculosis drug discovery and emerging targets. Ann N Y Acad Sci.

[14] Tonge, P. J. Drug−target kinetics in

[15] Sala C, Dhar N, Hartkoorn RC, et al. Simple model for testing drugs against

Chemother. 2010 Oct;54(10):4150-4158.

[16] Gold, B.; Nathan, C. Targeting phenotypically tolerant Mycobacterium tuberculosis. Microbiol. Spectr. 2017, 5,

[17] Rao SP, Lakshminarayana SB, Kondreddi RR, Herve M, Camacho LR, Bifani P, Kalapala SK, Jiricek J, Ma NL, Tan BH, Ng SH, Nanjundappa M, Ravindran S, Seah PG, Thayalan P,

[2] CDC "Tuberculosis Fact Sheets", Centers for Disease Control and

[3] World Health Organization. Multidrug and Extensively Drugresistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. WHO/HTM/TB/2010.3. Geneva,

Switzerland: WHO; 2010.

[4] WHO "Multidrug-Resistant

Tuberculosis (MDR-TB) 2016 Update", World Health Organization, 2016; http://www.who.int/tb/ challenges/ mdr/mdr\_tb\_factsheet.pdf accessed: 29

[5] Sarathy, J. P.; Zuccotto, F.; Hsinpin, H.; Sandberg, L.; Via, L. E.; Marriner, G. A.; Masquelin, T.; Wyatt, P.; Ray, P.;

Dartois, V. Prediction of Drug Penetration in Tuberculosis Lesions. ACS Infect. Dis. 2016, 12;2(8):552-63.

[6] Harvey AL, Edrada-Ebel R,

2015 Feb;14(2):111-129.

2016, 2, 16076.

Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov.

[7] Pai, M.; Behr, M. A.; Dowdy, D.; Dheda, K.; Divangahi, M.; Boehme, C. C.; Ginsberg, A.; Swaminathan, S.; Spigelman, M.; Getahun, H.; et al. Tuberculosis. Nat. Rev. Dis. Primers

[8] Kumar, A., Chettiar, S., & Parish, T. (2016). Current challenges in drug discovery for tuberculosis. Expert Opinion on Drug Discovery, *12*(1), 1-4.

Prevention, 2014; https://www.cdc.gov/ tb/publications/ factsheets/general/ ltbiandactivetb.htm accessed: 22

tuberculosis. Nature. 2011 Jan 27;469(7331):483-490. DOI:10.1038/

**References**

nature09657

December 2017.

September 2017.

*Challenges in Drug Discovery against Tuberculosis DOI: http://dx.doi.org/10.5772/intechopen.97857*
